Long-Acting Injectable ART Superior to Oral Regimens in Patients with HIV Adherence Challenges: Insights from the LATITUDE Trial

Highlight

• Monthly long-acting injectable cabotegravir plus rilpivirine (LA-ART) demonstrated a 22.8% regimen failure rate compared to 41.2% for standard oral therapy at 48 weeks.
• The LATITUDE trial was stopped early due to the clear superiority of the injectable regimen in a population previously considered ‘difficult to treat’ due to adherence challenges.
• The study highlights the potential for long-acting therapies to bridge the health equity gap for patients facing socioeconomic or structural barriers to daily pill-taking.

Background: The Persistent Challenge of ART Adherence